Morgan Stanley Increases Centessa Pharmaceuticals (NASDAQ:CNTA) Price Target to $11.00

Centessa Pharmaceuticals (NASDAQ:CNTA) had its target price lifted by equities researchers at Morgan Stanley from $8.00 to $11.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective would indicate a potential upside of 20.88% from the company’s current price.

Separately, BMO Capital Markets reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Centessa Pharmaceuticals in a research report on Monday, April 1st. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.50.

Centessa Pharmaceuticals Trading Up 2.7 %

NASDAQ:CNTA opened at $9.10 on Friday. The company has a market cap of $914.37 million, a PE ratio of -6.41 and a beta of 1.39. The company has a current ratio of 10.37, a quick ratio of 10.37 and a debt-to-equity ratio of 0.36. Centessa Pharmaceuticals has a 12 month low of $5.15 and a 12 month high of $12.45. The company has a 50 day simple moving average of $9.18 and a two-hundred day simple moving average of $9.19.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its earnings results on Monday, May 13th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.03. Research analysts forecast that Centessa Pharmaceuticals will post -1.71 earnings per share for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 51,160 shares of the business’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $11.88, for a total value of $607,780.80. Following the transaction, the insider now directly owns 71,525 shares in the company, valued at approximately $849,717. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 11.59% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Rathbones Group PLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at about $203,000. Affinity Asset Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 13.0% during the third quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock valued at $6,587,000 after acquiring an additional 117,368 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of Centessa Pharmaceuticals by 25.8% during the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock worth $18,313,000 after buying an additional 580,500 shares in the last quarter. Acuta Capital Partners LLC acquired a new position in Centessa Pharmaceuticals in the 3rd quarter valued at $2,092,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 371.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,394 shares of the company’s stock valued at $51,000 after buying an additional 5,037 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.